Overview
Herpes zoster myelitis, also known as zoster myelitis, is a rare but serious complication of varicella-zoster virus (VZV) reactivation that affects the spinal cord. This condition typically arises in individuals with a prior history of chickenpox, where the latent VZV reactivates, often due to immunosuppression or aging. The involvement of the spinal cord can lead to a spectrum of neurological deficits, including pain, sensory disturbances, motor weakness, and autonomic dysfunction. Understanding the pathophysiology, recognizing clinical manifestations, and implementing appropriate management strategies are crucial for optimizing patient outcomes. While the evidence base for herpes zoster myelitis is somewhat limited compared to more common manifestations of herpes zoster, emerging research provides valuable insights into potential mechanisms and therapeutic approaches.
Pathophysiology
Herpes zoster myelitis occurs when the latent VZV reactivates within the dorsal root ganglia and subsequently spreads centrally to involve the spinal cord. The study by [PMID:16288901] elucidates mechanisms underlying hyperalgesia, suggesting that periodic sensitization and activation of C nociceptors play a pivotal role. This sensitization likely mirrors the processes seen in herpes zoster myelitis, where both myelinated and unmyelinated sensory neurons are affected. The reactivation of VZV in the spinal cord leads to inflammation and direct neuronal damage, disrupting normal sensory and motor pathways. This disruption can manifest as hyperalgesia, allodynia, and neuropathic pain, reflecting the involvement of both central and peripheral nervous system components. In clinical practice, these symptoms underscore the importance of early recognition and intervention to mitigate neuronal damage and alleviate patient suffering.
The inflammatory response triggered by VZV reactivation not only affects sensory neurons but also involves microglia and astrocytes within the spinal cord, contributing to further neuronal injury and functional impairment. This multifaceted pathophysiology highlights the complexity of managing herpes zoster myelitis, emphasizing the need for comprehensive therapeutic strategies that address both the viral infection and the resultant neuroinflammation.
Diagnosis
Diagnosing herpes zoster myelitis requires a high index of suspicion, particularly in patients with a history of chickenpox and presenting with neurological symptoms following a prodromal phase of rash or without a rash. Clinical features often include acute onset of radiculopathy, sensory deficits, motor weakness, and autonomic disturbances. Magnetic resonance imaging (MRI) of the spine frequently reveals characteristic T2 hyperintensities within the spinal cord, indicative of inflammation or demyelination. Lumbar puncture may show elevated protein levels and pleocytosis in the cerebrospinal fluid (CSF), although these findings can be nonspecific. Electromyography (EMG) and nerve conduction studies can further support the diagnosis by demonstrating peripheral nerve involvement or denervation changes.
Given the rarity and variability of presentations, a multidisciplinary approach involving neurology, infectious disease, and sometimes neuroradiology is often necessary for accurate diagnosis. Early neuroimaging and CSF analysis are critical in distinguishing herpes zoster myelitis from other causes of spinal cord syndromes, such as transverse myelitis or compressive lesions. Prompt recognition is essential to initiate timely antiviral therapy and supportive care, which can significantly impact patient outcomes.
Management
Antiviral Therapy
The cornerstone of managing herpes zoster myelitis involves prompt initiation of antiviral therapy to suppress VZV replication. Acyclovir, valacyclovir, and famciclovir are commonly used agents, with valacyclovir and famciclovir offering advantages due to their higher bioavailability and longer half-lives. These medications should be administered intravenously initially, especially in severe cases, followed by oral continuation as clinically appropriate. The goal is to reduce viral load and mitigate further neuronal damage. While specific dosing regimens are not detailed in the provided evidence, clinical guidelines generally recommend high-dose intravenous therapy for several days followed by oral maintenance therapy for a total duration of 10 to 21 days, depending on the severity and response to treatment.
Symptomatic Treatment
Managing the neuropathic pain and hyperalgesia associated with herpes zoster myelitis is equally critical. The study by [PMID:16288901] highlights the potential of novel therapeutic approaches, such as the use of a recombinant herpes simplex vector, which demonstrated substantial and long-lasting antihyperalgesic and analgesic effects in primate models. Although this approach requires further clinical translation, it underscores the exploration of targeted gene therapy or vector-based interventions for managing localized pain syndromes. In current clinical practice, a multimodal approach is often employed, including:
Supportive Care
Supportive care measures are essential to address the multifaceted impact of herpes zoster myelitis. This includes:
Considerations in Specific Populations
In specific patient populations, such as obstetric patients, the management approach must be tailored carefully. A prospective randomized trial involving 100 obstetric patients with a history of herpes simplex labialis (HSL) undergoing cesarean delivery highlighted the increased risk of HSL reactivation in those receiving intrathecal morphine plus intravenous morphine (ITM+PCA group) compared to those receiving only intravenous morphine (PCA-only group) [PMID:15845709]. This underscores the importance of minimizing immunosuppression and carefully selecting analgesic regimens to prevent viral reactivation. Clinicians should consider alternative pain management strategies that reduce the risk of reactivation, such as regional anesthesia techniques or non-opioid analgesics, particularly in immunocompromised or high-risk individuals.
Complications
Herpes zoster myelitis can lead to a range of complications that significantly affect patient outcomes. One notable complication observed in the study by [PMID:15845709] is the increased incidence of pruritus, particularly in the early postoperative period among patients experiencing HSL reactivation. Pruritus can exacerbate discomfort and may necessitate additional symptomatic treatment with antihistamines or other antipruritic agents. Furthermore, the neurological deficits associated with spinal cord involvement can persist or worsen, leading to chronic disability, including motor deficits, sensory loss, and autonomic dysfunction. These complications highlight the need for vigilant monitoring and multidisciplinary management to address both acute and long-term sequelae effectively.
Long-term Neurological Sequelae
Long-term follow-up studies are limited but suggest that some patients may experience residual neurological deficits even after antiviral treatment. These can include persistent motor weakness, sensory disturbances, and neuropathic pain, underscoring the importance of ongoing rehabilitation and pain management strategies. Early intervention and comprehensive care plans are crucial to mitigate these long-term effects and improve functional outcomes.
Key Recommendations
These recommendations aim to guide clinicians in providing optimal care for patients with herpes zoster myelitis, balancing the urgency of antiviral intervention with the complexities of managing neuropathic symptoms and long-term complications.
References
1 Yeomans DC, Lu Y, Laurito CE, Peters MC, Vota-Vellis G, Wilson SP et al.. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Molecular therapy : the journal of the American Society of Gene Therapy 2006. link 2 Davies PW, Vallejo MC, Shannon KT, Amortegui AJ, Ramanathan S. Oral herpes simplex reactivation after intrathecal morphine: a prospective randomized trial in an obstetric population. Anesthesia and analgesia 2005. link
2 papers cited of 3 indexed.